Histone acetylation is a prominent epigenetic modification linked to the memory loss symptoms associated with neurodegenerative disease. The use of existing histone deacetylase inhibitor (HDACi) drugs for treatment is precluded by their weak blood-brain barrier (BBB) permeability and undesirable toxicity. Here, we address these shortcomings by developing a new class of disulfide-based compounds, inspired by the scaffold of the FDA-approved HDACi romidepsin (FK288).
View Article and Find Full Text PDFComplexation of the adjacent actinide ions americium(III) and curium(III) by the ligand N,N'-bis[(6-carboxy-2-pyridyl)methyl]-1,10-diaza-18-crown-6 (H2bp18c6) in aqueous solution was studied to quantify and characterize its americium/curium selectivity. Liquid-liquid extraction and spectrophotometric titration indicated the presence of both fully deprotonated and monoprotonated complexes, An(bp18c6)(+) and An(Hbp18c6)(2+) (An = Am or Cm), at the acidities that would be encountered when treating nuclear wastes. The stability constants of the complexes in 1 M NaNO3 determined using competitive complexation were log β101 = 15.
View Article and Find Full Text PDF